Preliminary Phase 1 Results of the PD-1 Inhibitor ABBV-181 in Japanese vs Western Patients With Advanced Solid Tumors

被引：0

作者：

Kuboki, Yasutoshi ^{[1
]}

Kondo, Shunsuke ^{[2
]}

Drew, Rasco ^{[3
]}

John, Powderly ^{[4
]}

Alexander, Spira ^{[5
]}

Jason, J. Luke ^{[6
]}

Daniel, Afar ^{[7
]}

Stefan, Englert ^{[8
]}

Hashiba, Hideyuki ^{[9
]}

Stacie, Lambert ^{[7
]}

Apurvasena, Parikh ^{[7
]}

Shimizu, Eisuke ^{[9
]}

Greg, Vosganian ^{[7
]}

Doi, Toshihiko ^{[1
]}

Yamamoto, Noboru ^{[2
]}

机构：

[1] Natl Canc Ctr Hosp East, Dept Expt Therapeut, Kashiwa, Chiba, Japan

[2] Natl Canc Ctr, Tokyo, Japan

[3] Methodist Hosp, San Antonio, TX USA

[4] Carolina BioOncol Inst, Huntersville, NC USA

[5] Virginia Canc Specialists, Fairfax, VA USA

[6] Univ Chicago Med, Chicago, IL USA

[7] AbbVie Inc, Redwood City, CA USA

[8] AbbVie Inc, Ludwigshafen, Germany

[9] AbbVie GK, Oncol TA, Clin Dev Solid Tumor, Tokyo, Japan

来源：

关键词：

D O I：

10.1093/annonc/mdz338.072

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

MO2 - 12 -

引用

页数：1